Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at the potential of Merus’ Petosemtamab (MCLA-158) and the Phase 2 data presented at ASCO in HNSCC.

Ticker(s): MRUS

Who's the expert?

Institution: Huntsman Cancer Institute

Thoracic and Head/Neck Oncologist
Treats more than 150 patients with HNSCC per year
Clinical and research interest in never-smokers lung cancer and patient reported outcomes (PROs)

Interview Goal

On this call we will be discussing the potential of Merus’ Petosemtamab (MCLA-158) in combination with pembrolizumab as a first line treatment option for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 2 data presented at ASCO.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.